Loading...
Loading...
In a report published Friday, Bank of America analyst Derik de Bruin reiterated an Underperform rating on
AffymetrixAFFX, and raised the price target from $7.00 to $7.50.
In the report, Bank of America noted, “Affymetrix is a pioneer in the development and commercialization of DNA microarray technology, but stiff competition, new technologies and shifting customer priorities have resulted in falling revenues and market share loss. The recent management changes are encouraging, but we expect shares to remain volatile and underperform until there is more visibility into the core business, as it is difficult to ascertain the underlying value.”
Affymetrix closed on Thursday at $7.69.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
We simplify the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in